UK markets closed

Prothena Corporation plc (0Y3M.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
54.76-3.49 (-6.00%)
At close: 06:02PM BST

Prothena Corporation plc

77 Sir John Rogerson’s Quay
Block C Grand Canal Docklands
Dublin 2
353 1 236 2500

Full-time employees127

Key executives

NameTitlePayExercisedYear born
Dr. Gene G. Kinney Ph.D.Pres, CEO & Director1.03M2.91M1969
Mr. Tran B. Nguyen M.B.A.CFO & Chief Strategy Officer762.86k3.84M1974
Mr. Brandon S. SmithChief Operating Officer756.41kN/A1975
Ms. Carol D. KarpChief Regulatory Officer697.51kN/A1953
Dr. Hideki Garren M.D., Ph.D.Chief Medical Officer809.59k526.1k1965
Ms. Karin L. Walker CPA, CPAChief Accounting Officer & ControllerN/AN/A1963
Dr. Wagner M. ZagoChief Scientific OfficerN/AN/A1973
Ms. Jennifer ZibudaDirector of Investor Relations & CommunicationN/AN/AN/A
Mr. Michael J. MalecekChief Legal Officer & Company Sec.N/AN/A1966
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease and other related synucleinopathies; NNC6019 that completed Phase I clinical trial for the treatment of ATTR amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease, as well as TDP-43 and PRX019 for the treatment of Alzheimer's disease and other neurodegenerative diseases. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

Corporate governance

Prothena Corporation plc’s ISS governance QualityScore as of 28 September 2023 is 4. The pillar scores are Audit: 9; Board: 3; Shareholder rights: 3; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.